Research and progress on biomarkers of neuromyelitis optica spectrum disorders
- PMID: 33019871
- DOI: 10.1080/10799893.2020.1830109
Research and progress on biomarkers of neuromyelitis optica spectrum disorders
Abstract
Neuromyelitis optica spectrum disorders (NMOSD) are a demyelinating disorder of the central nervous system based on the involvement of the optic nerve and/or spinal cord. The disease is characterized by high recurrence and disability. NMOSD is mainly diagnosed by AQP4-IgG and MOG-IgG. However, there are still some patients with negative or undetermined double-antibody, and AQP4-IgG and MOG-IgG cannot indicate the clinical disease activity. Therefore, it is urgent to explore interesting biomarkers in serum and cerebrospinal fluid to promote early clinical diagnosis and/or as a target for diagnosis and treatment. This article summarized the research progress in serum and cerebrospinal fluid biomarkers of astrocytes, neurons, myelin sheath, and other damage after the onset of NMOSD. Besides the value of microglial activation-related proteins in the diagnosis and treatment of NMOSD was prospected, so as to promote the research progress of NMOSD.
Keywords: Neuromyelitis optica spectrum disease; biomarkers; microglia.
Similar articles
-
The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.Mult Scler Relat Disord. 2019 Oct;35:1-4. doi: 10.1016/j.msard.2019.06.035. Epub 2019 Jun 29. Mult Scler Relat Disord. 2019. PMID: 31276911
-
Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.J Neurol Sci. 2017 Oct 15;381:240-244. doi: 10.1016/j.jns.2017.08.3254. Epub 2017 Aug 31. J Neurol Sci. 2017. PMID: 28991690
-
Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.J Neuroinflammation. 2021 May 1;18(1):105. doi: 10.1186/s12974-021-02138-7. J Neuroinflammation. 2021. PMID: 33933106 Free PMC article.
-
Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.Rev Neurol (Paris). 2018 Jun;174(6):458-470. doi: 10.1016/j.neurol.2018.02.084. Rev Neurol (Paris). 2018. PMID: 29685427 Review.
-
[From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification].Nervenarzt. 2021 Apr;92(4):307-316. doi: 10.1007/s00115-021-01098-w. Epub 2021 Mar 16. Nervenarzt. 2021. PMID: 33728474 Review. German.
Cited by
-
Biomarkers in autoimmune diseases of the central nervous system.Front Immunol. 2023 Apr 5;14:1111719. doi: 10.3389/fimmu.2023.1111719. eCollection 2023. Front Immunol. 2023. PMID: 37090723 Free PMC article. Review.
-
Effects of C5a and Receptor CD88 on Glutamate and N-Methyl-D-Aspartic Acid Receptor Expression in the Mouse Model of Optic Neuromyelitis.Comput Math Methods Med. 2022 Apr 25;2022:4997393. doi: 10.1155/2022/4997393. eCollection 2022. Comput Math Methods Med. 2022. PMID: 35509858 Free PMC article.
-
An Update on the Laboratory Diagnosis of Neuromyelitis Optica Spectrum Disorders.J Clin Neurol. 2022 Mar;18(2):152-162. doi: 10.3988/jcn.2022.18.2.152. J Clin Neurol. 2022. PMID: 35274835 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
